Back to top

FDA Approves Expanded Indication for AJOVY (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine | TEVA Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Teva Pharmaceutical Industries Ltd. (TEVA)